Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable Stage IIA-IIIA NSCLC: A Multicenter, Two-Arm, Phase II Exploratory Trial
Shuyu Ji(Tongji University), Yuming Zhu(Third People 's Hospital of Chongqing), Dongliang Bian(Tongji University), Biyun Qian(Shanghai Jiao Tong University), Minwei Bao(Tongji University), Zhenxin Sheng(Tongji University), Ziyun Shen(Tongji University), Wentian Zhang(Tongji University), Peng Zhang(Tongji University), Haifeng Wang(China-Japan Friendship Hospital), Han Zhang(Guangzhou University of Chinese Medicine), Lele Zhang(Tongji University), Xinsheng Zhu(Ministry of Ecology and Environment), Huansha Yu(Shanghai Pulmonary Hospital), Jie Huang(Tongji University), Fenghuan Sun(Tongji University), Nan Song(Tongji University), Kaiqi Jin(Tongji University), Haoran Xia(Tongji University)
Cited by 0
Related Papers
The cytotoxicity of cadmium-based quantum dots
|Biomaterials|2011|711
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
|Genome Medicine|2023|369